Therefore, high level of systemic inflammation not only means that NSCLC patients may have more adverse risk factors, but also that NSCLC patients may have worse clinical outcome when treated with EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.